

Datasheet for 200-4333S**Ovalbumin Antibody Peroxidase Conjugated****Overview**

Description:	Anti-Ovalbumin (Hen Egg White) (RABBIT) Antibody Peroxidase Conjugated - 200-4333S
Item No.:	200-4333S
Size:	25 µL
Applications:	ELISA, WB
Reactivity:	Chicken
Host Species:	Rabbit

Product Details

Background:	Anti-Ovalbumin Antibody detects Ovalbumin. Ovalbumin is the main protein found in egg white, making up 60-65% of the total protein. It is a non-inhibitory serpin. It is the storage protein of egg white. Anti-Ovalbumin Antibody is ideal for investigators involved in Cell Signaling, Immunology and Signal Transduction research.
Synonyms:	rabbit anti-Ovalbumin Antibody Peroxidase Conjugation, HRP conjugated rabbit anti-Ovalbumin antibody, Egg albumin antibody, Plakalbumin, Allergen Gal d II, Allergen=Gal d 2, Hen Egg White
Host Species:	Rabbit
Conjugate:	Peroxidase (HRP)
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	SERPINB14
Reactivity:	Chicken
Immunogen Type:	Native Protein
Immunogen:	Anti-Ovalbumin Antibody was produced by repeated immunizations with hen egg white Ovalbumin protein.

Purity/Specificity: Ovalbumin Antibody is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Peroxidase, anti-Rabbit Serum as well as purified and partially purified Ovalbumin [Hen Egg White]. Cross reactivity against Ovalbumin from other tissues and species may occur but have not been specifically determined.

Relevant Links:

- [200-4333 SDS](#)
- [UniProtKB - P01012](#)
- [NCBI - P01012.2](#)
- [GeneID - 396058](#)

Application Details

Tested Applications: ELISA, WB

Application Note: Anti-Ovalbumin Antibody Peroxidase Conjugated has been tested by ELISA and western blot and is suitable for IHC and IP. Researchers should determine optimal titers for applications that are not stated below.

Assay Dilutions: All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

ELISA: 1:5,000 - 1:25,000

IHC: 1:500 - 1:2,500

IP: 1:100

WB: 1:1,000 - 1:5,000

Formulation

Physical State: Liquid (sterile filtered)

Concentration: 1.0 mg/mL by UV absorbance at 280 nm

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative: 0.01% (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!

Stabilizer: 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free


Shipping & Handling

Shipping Condition: Dry Ice

Storage Condition: Store vial at -20° C or below prior to opening. This vial contains a relatively low volume of reagent (25 µL). To minimize loss of volume dilute 1:10 by adding 225 µL of the buffer stated above directly to the vial. Recap, mix thoroughly and briefly centrifuge to collect the volume at the bottom of the vial. Use this intermediate dilution when calculating final dilutions as recommended below. Store the vial at -20°C or below after dilution. Avoid cycles of freezing and thawing.


Expiration: Expiration date is one (1) year from date of receipt.

Images




ELISA

Humoral immune responses against OVA and GFP were assessed after neonatal AAV injections and OVA and GFP vaccinations by ELISA. Two-fold serial dilutions of serum were prepared beginning from 1:5 to 1:640. Results are reported as the optical density (OD) after absorbance reading at 492 nm. (#1, #2: nonhuman primates administered saline at birth and AAV at 4 months of age; #3: nonhuman primate administered AAV at birth and at 4 months of age.) Fig 4. PMID: 26333349



ELISA


Timeline for the AAV-redosing experiment (A) and the description of the rAAV serotype and OVA transgene specific for each injection (B). C57BL/6 male mice, 6 weeks old, were injected i.m. with either rAAV1.OVA or rAAV1.OVA.142BS (1×10^{11} GCs/mouse). The same mice were then redosed with either rAAV8.OVA or rAAV8.OVA.142BS (1×10^{11} GCs/mouse) i.m. 4 weeks after the first injection ($n = 5$). (C and D) ELISA quantification of circulating OVA expression (C) and anti-OVA IgG (D) in vector-injected mice. Sera were collected throughout a 12-week period. Box plots with whiskers correspond to mean $\pm$ SD and maximum and minimum values. P values were determined by ANOVA with Tukey's post hoc test for pairwise comparison. Asterisks (*) denote test of significance between injection groups 1 and 3, and hashes (#) denote test of significance between injection groups 2 and 4. P values for longitudinal comparisons were determined by repeated measures with 2-way ANOVA. Daggers (†) denote test of significance. *,#P < 0.05, **,###P < 0.01, ***,###,†††P < 0.001. Fig 4. PMID: 31112525



ELISA


Incorporation of miR-223BSs and miR-652BSs boosts in vivo OVA production and suppresses antibody development. (A) Endogenous miRNA expression levels in cultured mouse myoblasts (C2C12), myocytes (dC2C12), macrophages (RAW264.7), DCs (JAWSII), bone marrow derived macrophages (BMDM), primary mouse hepatocytes, and Kupffer cells as quantified by reverse transcription quantitative PCR (RT-qPCR) ($n = 3$). rAAV1 expression vectors were injected by i.m. on day 0 followed by serum collection every week for an eight-week period. (B, C) ELISA quantification of circulating OVA expression (B) and anti-OVA IgG1 (C) (1×10^{11} GCs/mouse, $n = 10$). Single gradient heat map representing respective analyte levels ($n = 5$). (D–F) ddPCR detection of rAAV vector genome copies in injected skeletal muscle (D), spleen (E), and liver (F) at eight weeks post-injection ($n = 5$). Values represent mean $\pm$ SD. *p < 0.05, ***p < 0.001, one-way ANOVA with Tukey's post hoc test. Fig 2.

PMID: 33995418



Western Blot

Western Blot of Rabbit anti-Ovalbumin Peroxidase Conjugated Antibody. Lane 1: Ovalbumin (Hen Egg). Load: 50 ng per lane. Primary antibody: Rabbit anti-Ovalbumin Peroxidase Conjugated Antibody at 1:1,000 overnight at 4°C. Secondary antibody: none Block: MB-070 for 30 min at RT. Predicted/Observed size: 43 kDa, 43 kDa for Ovalbumin. Other band(s): Ovalbumin splice variants and isoforms.



Western Blot

Western Blot of Rabbit anti-Ovalbumin Peroxidase Conjugated Antibody. Lane 1: Ovalbumin. Lane 2: None. Load: 50 ng per lane. Primary antibody: Rabbit anti-Ovalbumin Peroxidase Conjugated Antibody at 1:1,000 overnight at 4°C. Secondary antibody: none Block: MB-070 for 30 min at RT. Predicted/Observed size: 43 kDa, 43 kDa for Ovalbumin. Other band(s): Ovalbumin splice variants and isoforms.

References

- Rana J et al. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver. *Mol Ther Methods Clin Dev.* (2024)
- Muhuri M et al. Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction. *Front Immunol.* (2021)
- Xiao Y et al. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. *JCI Insight.* (2019)
- Tai et al. Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: preliminary studies. *Gene Therapy* (2015)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.